NOVN.SW
Price:
$93.96
Market Cap:
$212.89B
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients an...[Read more]
Industry
Drug Manufacturers - General
IPO Date
1995-08-03
Stock Exchange
SIX
Ticker
NOVN.SW
According to Novartis AG’s latest financial reports and current stock price. The company's current PE Ratio is 18.91. This represents a change of 27.89% compared to the average of 14.79 of the last 4 quarters.
The mean historical PE Ratio of Novartis AG over the last ten years is 19.70. The current 18.91 PE Ratio has changed 9.50% with respect to the historical average. Over the past ten years (40 quarters), NOVN.SW's PE Ratio was at its highest in in the December 2019 quarter at 47.75. The PE Ratio was at its lowest in in the December 2021 quarter at 3.02.
Average
19.70
Median
21.12
Minimum
8.22
Maximum
30.41
Discovering the peaks and valleys of Novartis AG PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 245.08%
Maximum Annual PE Ratio = 30.41
Minimum Annual Increase = -69.18%
Minimum Annual PE Ratio = 8.22
Year | PE Ratio | Change |
---|---|---|
2023 | 14.12 | -50.21% |
2022 | 28.35 | 245.08% |
2021 | 8.22 | -69.18% |
2020 | 26.65 | -12.35% |
2019 | 30.41 | 118.65% |
2018 | 13.91 | -38.82% |
2017 | 22.73 | -0.14% |
2016 | 22.77 | 120.22% |
2015 | 10.34 | -47.00% |
2014 | 19.50 | 4.09% |
The current PE Ratio of Novartis AG (NOVN.SW) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
16.89
5-year avg
21.55
10-year avg
19.70
Novartis AG’s PE Ratio is less than Roche Holding AG (20.15), less than Nestlé S.A. (18.96), greater than Zurich Insurance Group AG (17.76), greater than Swiss Re AG (12.46), less than UBS Group AG (55.50),
Company | PE Ratio | Market cap |
---|---|---|
20.15 | $217.57B | |
18.96 | $208.96B | |
17.76 | $74.21B | |
12.46 | $32.44B | |
55.50 | $86.78B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Novartis AG using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Novartis AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Novartis AG's PE Ratio?
How is the PE Ratio calculated for Novartis AG (NOVN.SW)?
What is the highest PE Ratio for Novartis AG (NOVN.SW)?
What is the 3-year average PE Ratio for Novartis AG (NOVN.SW)?
What is the 5-year average PE Ratio for Novartis AG (NOVN.SW)?
How does the current PE Ratio for Novartis AG (NOVN.SW) compare to its historical average?